NCT02767661: Metronomic Capecitabine Plus Aromatase Inhibitor for First Line Treatment in HR(+), Her2(-) Metastatic Breast Cancer

NCT02767661
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER++
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 3
Drug Category: Endocrine (Hormone) Therapy, Chemotherapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years to 70 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: Patients must have ER++ tumor(s)
Exclusions: Patients with known uncontrolled or symptomatic central nervous system metastases
https://ClinicalTrials.gov/show/NCT02767661

Comments are closed.

Up ↑